Soluble anions in gastrointestinal lumen

Soluble anions in the gastrointestinal (GI) lumen encompass a variety of negatively charged ions, such as phosphate, bile acids, and oxalate, which play significant roles in human physiology and disease (StatPearls: NBK537102). These anions are therapeutic targets primarily through the use of oral binding agents that sequester them within the gut to prevent their absorption into the systemic circulation (PMID: 25133510). For example, phosphate binders are a cornerstone of therapy for hyperphosphatemia in patients with chronic kidney disease, working by forming insoluble complexes with dietary phosphate. Bile acid sequestrants are used to treat hypercholesterolemia by interrupting the enterohepatic circulation of bile acids, thereby stimulating the liver to convert more cholesterol into bile acids (StatPearls: NBK537102). Additionally, targeting luminal oxalate is a strategy used to reduce the risk of calcium oxalate kidney stones in patients with enteric hyperoxaluria (PMCID: PMC4525130). Because these targets are located within the lumen, the drugs interacting with them are typically non-absorbable, minimizing systemic side effects but often causing local gastrointestinal symptoms. The clinical utility of targeting these anions lies in the ability to modulate systemic metabolic pathways without requiring drug entry into the bloodstream.

Other names

Luminal anionsIntestinal anionsGastrointestinal anions

Sequestration and binding of anions within the gastrointestinal lumen to prevent systemic absorption and promote fecal excretion.